Hypothyroidism reduces glutamate-synaptic release by ouabain depolarization in rat CA3-hippocampal region. 2012

K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
Departamento de Fisiología Mauricio Russek, Escuela Nacional de Ciencias Biológicas, IPN, México D.F., México.

Thyroid hormones modulate the physiology of the hippocampus in humans, where glutamate plays an important role as neurotransmitter. The aim of this work was to study the effect of hypothyroidism on hippocampal glutamate extracellular levels, release, uptake, and synthesis. The effects of PDC (a glutamate transporter inhibitor) and ouabain (a Na(+) /K(+) -ATPase inhibitor) infusion on microdialysate glutamate and aspartate levels of CA3 hippocampal region were evaluated. Animals were assigned to one of the following groups: hypothyroid group (Hyp), receiving methimazole (anantithyroid drug); replacement group (Hyp + T(4) ), receiving antithyroid treatment plus thyroxine; and euthyroid control group (Eut). Dialysate fractions were collected every 15 min to determine basal glutamate levels for 1 hr. Then, PDC (10 mM) or ouabain (100 μM) was infused for 30 min. Results showed lower glutamate and aspartate basal levels in Hyp than in Eut groups. PDC infusion increased amino acids levels in all groups, whereas ouabain infusion increased glutamate and aspartate levels only in the Eut group. The infusion of tetrodotoxin (TTX; a voltage-gated sodium channel inhibitor) prevented the glutamate increase in euthyroid rats. The Hyp + T(4) group showed glutamate levels similar to those found in the Eut group. Additionally, glutaminase activity in hippocampus was lower in the Hyp group than in the Eut or Hyp + T(4) group. Results suggest that high-affinity glutamate transporters are not altered by hypothyroidism; however, decreased hypotyroidism reduced vesicular glutamate release in the CA3-hippocampal region as a consequence of diminished glutamate synthesis.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D008297 Male Males
D008713 Methimazole A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Methymazol,Thiamazole,1-Methyl-2-mercaptoimidazole,Favistan,Mercasolyl,Mercazol,Mercazole,Mercazolyl,Merkazolil,Methizol,Methylmercaptoimidazole,Metisol,Metizol,Strumazol,Tapazole,Thiamazol Henning,Thiamazol Hexal,Thimazol,Thyrozol,Tiamazol,Tirodril,1 Methyl 2 mercaptoimidazole,Henning, Thiamazol,Hexal, Thiamazol
D010042 Ouabain A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. Acocantherin,G-Strophanthin,Acolongifloroside K,G Strophanthin
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005972 Glutaminase Phosphate-Activated Glutaminase,Glutaminase, Phosphate-Activated,Phosphate Activated Glutaminase
D005974 Glutamate-Ammonia Ligase An enzyme that catalyzes the conversion of ATP, L-glutamate, and NH3 to ADP, orthophosphate, and L-glutamine. It also acts more slowly on 4-methylene-L-glutamate. (From Enzyme Nomenclature, 1992) EC 6.3.1.2. Glutamine Synthetase,Glutamate Ammonia Ligase (ADP),Glutamate Ammonia Ligase,Ligase, Glutamate-Ammonia,Synthetase, Glutamine
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
January 2020, Frontiers in synaptic neuroscience,
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
January 2002, Proceedings of the Western Pharmacology Society,
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
January 2016, Frontiers in neuroscience,
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
June 1989, Sheng li xue bao : [Acta physiologica Sinica],
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
May 1996, Neuroreport,
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
July 2013, BMC neuroscience,
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
January 2023, Molecules (Basel, Switzerland),
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
January 1990, The European journal of neuroscience,
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
September 1989, The Journal of physiology,
K B Sánchez-Huerta, and S Montes, and F Pérez-Severiano, and C Alva-Sánchez, and C Ríos, and J Pacheco-Rosado
March 2017, Journal of pharmacological sciences,
Copied contents to your clipboard!